

Date: March 4, 2004



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Simard, et al.  
Appl. No. : 10/657,022  
Filed : September 5, 2003  
For : EPITOPE SEQUENCES  
Examiner : Unknown  
Group Art Unit : 1645

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 4, 2004

(Date)

Marc T. Morley, Reg. No. 52,051

## TRANSMITTAL LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing ninety-five (95) references; seventy-two (72) of which are enclosed.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marc T. Morley  
Registration No. 52,051  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

**INFORMATION DISCLOSURE STATEMENT**

Applicant	:	Simard, et al.
App. No.	:	10/657,022
Filed	:	September 5, 2003
For	:	EPITOPE SEQUENCES
Examiner	:	Unknown
Group Art Unit	:	1645

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing ninety-five (95) references; seventy-two (72) of which are enclosed. Copies of disclosed U.S. patents and/or publications are not included pursuant to PTO waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of other references, if listed, are enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP


Dated: March 4, 2004

By: M. T. Morley  
Marc T. Morley  
Registration No. 52,051  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
MANNK.032AAPPLICATION NO.  
10/657,022INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Simard, et al.FILING DATE  
September 5, 2003GROUP  
1645

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	5,683,886	11/04/97	van der Brugger, et al.			
	2.	5,342,774	03/30/94	Boon, et al.			
	3.	5,445,939	08/29/95	Anderson			
	4.	5,538,866	07/23/96	Israeli, et al.			
	5.	5,571,711	11/05/96	van der Bruggen, et al.			
	6.	5,610,013	03/11/97	Van den Eynde, et al.			
	7.	5,635,363	06/03/97	Altman, et al.			
	8.	5,648,226	07/15/97	Van den Eynde, et al.			
	9.	5,656,446	08/12/97	Anderson			
	10.	5,747,271	05/05/98	Boon-Falleur, et al.			
	11.	5,804,381	09/08/98	Chen, et al.			
	12.	5,830,753	11/03/98	Coulie, et al.			
	13.	5,830,755	11/03/98	Nishimura, et al.			
	14.	5,844,075	12/01/98	Kawakami, et al.			
	15.	5,856,136	01/05/99	Au-Young			
	16.	5,858,689	01/12/99	van der Bruggen, et al.			
	17.	5,935,818	08/10/99	Israeli, et al.			
	18.	5,993,828	11/30/99	Morton			
	19.	6,013,481	01/11/00	DeBacker, et al.			
	20.	6,015,884	01/18/00	Schneck, et al.			
	21.	6,025,191	02/15/00	Pfreundschuh			
	22.	6,069,001	05/30/00	Van den Eynde, et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	23.	WO 97/41440	11/06/97	PCT				

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
MANNK.032AAPPLICATION NO.  
10/657,022INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Simard, et al.FILING DATE  
September 5, 2003GROUP  
1645

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	24.	WO 99/02183	01/21/99	PCT				
	25.	WO 01/82963	11/08/01	PCT				
	26.	WO 02/081646	10/17/02	PCT				
	27.	WO 02/069907	02/12/02	PCT				
	28.	WO 02/062368	08/15/02	PCT				
	29.	WO 03/063770	08/07/03	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	30.	Aharoni, et al. "Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-la complex." <i>Nature</i> . 351: 147-150, (1991).						
	31.	Ambrosini, G. et al. "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma," [Abstract]. <i>Nat. Med.</i> 3: 917-921, (1997).						
	32.	Andersen, et al. "A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells." <i>Proc. Natl. Acad. Sci. USA</i> . 93: 1820-1824, (1996).						
	33.	Borsi, L. et al. "Differential Expression of the Fibronectin Isoform Containing the ED-B Oncofetal Domain in Normal Human Fibroblast Cell Lines Originating from Different Tissues." <i>Exp. Cell Res.</i> 199: 98-105, (1992).						
	34.	Carnemolla, B. et al. "A Tumor-associated Fibronectin Isoform Generated by Alternative Splicing of Messenger RNA Precursors." <i>J. Cell Biol.</i> 108: 1139-1148, (1989).						
	35.	Castellani, P. et al. "The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas." <i>Acta Neurochir. (Wien)</i> 142: 277-282, (2000).						
	36.	Castellani, P. et al. "The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis." <i>Int. J. Cancer</i> 59: 612-618, (1994).						
	37.	Cebon, et al. "Phase I Studies of Immunization with Melan-A and IL-12 in HLA A2+ Positive Patients with Stage III and IV Malignant Melanoma," [Abstract 1680], American Society of Clinical Oncology 35 <sup>th</sup> annual Meeting, Atlanta (1999).						
	38.	Chaux, et al. "Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by <i>In Vitro</i> with Dendritic Cells Transduced with MAGE-A1," <i>J. Immunol.</i> 163(5): 2928-2936 (1999).						
	39.	Chen, et al. "Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1." <i>J. Immunol.</i> 165: 948-955, (2000.).						
	40.	Chevalier. "Increased Expression of the Ed-B-Containing Fibronectin (An Embryonic Isoform of Fibronectin) in Human Osteoarthritic Cartilage." <i>Br. J. Rheumatol.</i> 35: 407-415, (1996).						
	41.	Chung et al. "Induction of Cytotoxic T Lymphocytes with Peptides <i>In Vitro</i> : Identification of Candidate T-Cell Epitopes in Hepatitis B Virus X Antigen." <i>J. Immunother.</i> 22: 279-287, (1999).						
	42.	Chung, D. H., et al. "NK and CTL Recognition of a Single chain H-2D Molecule: Distinct Sites of H-2D Interact with NK and TCR." <i>J. Immunol.</i> 163: 3699-3708, (1999).						

EXAMINER


DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
MANNK.032AAPPLICATION NO.  
10/657,022INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Simard, et al.FILING DATE  
September 5, 2003GROUP  
1645

(USE SEVERAL SHEETS IF NECESSARY)



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
(Listed only)t	43.	"Measurement of MHC/Peptide Interactions by Gel Filtration." <i>Current Protocols in Immunology</i> , John Wiley and Sons, New York, 18.3.1-18.3.19, (1998).
	44.	Dadaglio, et al. "Characterization and Quantitation of Peptide-MHC Complexes Produced from Hen Egg Lysozyme Using a Monoclonal Antibody." <i>Immunity</i> . 6: 727-738, (1997).
	45.	Dela Cruz, et al. "Creating HIV-1 reverse transcriptase cytotoxic T lymphocyte target structures by HLA-A2 heavy chain modifications." <i>Int. Immunol.</i> 12:1293-1302, (2000).
	46.	Di Fiore, et al. "erbB-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells." <i>Science</i> . 237: 178-182, (1987).
	47.	Dietrich, et al. "Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide <i>Listeria monocytogenes</i> ." <i>Nat. Biotech.</i> 16: 181-185, (1998).
	48.	Duc, et al. "Monoclonal antibodies directed against T cell epitopes presented by class I MHC antigens." <i>Int. Immunol.</i> 5: 427-431, (1993).
	49.	Eastman, et al. "A study of complexes of class II invariant chain peptide: major histocompatibility complex class II molecules using a new complex-specific monoclonal antibody." <i>Eur. J. Immunol.</i> 26: 385-393, (1996).
	50.	Engberg, et al. "Recombinant antibodies with the antigen-specific, MHC restricted specificity of T cells: novel reagents for basic and clinical investigations and immunotherapy." <i>Immunotechnology</i> . 4: 273-278, (1999).
	51.	Farnoud, M.R. et al. "Fibronectin Isoforms are Differentially Expressed in Normal and Adenomatous Human Anterior Pituitaries." <i>Int. J. Cancer</i> . 61: 27-34, (1995).
	52.	Franco, et al. "Epitope affinity for MHC class I determines helper requirement for CTL priming." <i>Nature Immunol.</i> 1(2): 145-150, (2002).
	53.	Gabler, U. et al. "Matrix remodeling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants." <i>Heart</i> . 75: 358-362, (1996).
	54.	Gold and Freedman. "Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques." <i>J. Exp. Med.</i> 121: 439-462, (1965). Fuller references can be found in the Online Medelian Inheritance in Man; record *114890.
	55.	Gure, A.O. et al. "SSX: A Multigene Family with Several Members Transcribed in Normal Testis and Human Cancer." <i>Int. J. Cancer</i> . 72: 965-971, (1997).
	56.	Kaczmarek, et al. "Distribution of Oncofetal Fibronectin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues." <i>Int. J. Cancer</i> . 59: 11-16, (1994).
	57.	Kalergis, et al. "Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMCH complex." <i>Nature Immunol.</i> 2: 229-234, (2001).
	58.	Karelina, T.V. and A.Z. "Interstitial Collagenase and the ED-B Oncofetal Domain of Fibronectin Are Markers of Angiogenesis in Human Skin Tumors." <i>Cancer Detect. Prev.</i> 22: 438-444, (1998).
	59.	Lebowitz, M.S. et al. "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses." <i>Cell Immunol.</i> 192: 175-184, (1999).
	60.	Lee, et al. "Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active $\beta_2$ -microglobulin domain." <i>Eur. J. Immunol.</i> 24: 2633, (1994).
	61.	Loridon-Rosa, et al. "Distribution of Oncofetal Fibronectin in Human Mammary Tumors: Immunofluorescence Study on Histological Sections." <i>Cancer Res.</i> 50: 1608-1612, (1990).
	62.	Madden. "The Three-Dimensional Structure of Peptide-MHC Complexes." <i>Annu. Rev. Immunol.</i> 13: 587-622, (1995).

EXAMINER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
MANNK.032AAPPLICATION NO.  
10/657,022INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Simard, et al.FILING DATE  
September 5, 2003GROUP  
1645EXAMINER  
INITIAL

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- |     |   |
|-----|---|
| 63. | Mage, et al. "A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity." <i>Proc. Natl. Acad. Sci. USA</i> . 89: 10658, (1992).  |
| 64. | Mandel, et al. "Oncofetal fibronectins in oral carcinomas: Correlation of two different types." <i>APMIS</i> . 102: 695-702, (1994).  |
| 65. | Matsuura, H. and S. Hakomori. "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma." <i>Proc. Natl. Acad. Sci. USA</i> . 82: 6517-6521, (1985). |
| 66. | Midulla. "Source of Oncofetal ED-B-containing Fibronectin: Implications of Production by Both Tumor and Endothelial Cells." <i>Cancer Res</i> . 60: 164-169, (2000).  |
| 67. | Mottez, et al. "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide Are Highly Immunogenic." <i>J. Exp. Med</i> . 181: 493, (1995).   |
| 68. | Neri, et al. "Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform." <i>Nat. Biotech</i> . 15:1271-1275, (1997).  |
| 69. | Nicolo, et al. "Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer." <i>Cell Differ. Dev</i> . 32: 401-408, (1990).  |
| 70. | Oehen, et al. "Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA." <i>Immunology</i> . 99, 163-169, (2000).   |
| 71. | Oyama, F. et al. "Coordinate Oncodevelopmental Modulation of Alternative Splicing of Fibronectin Pre-Messenger RNA at ED-A, ED-B, and CS1 Regions in Human Liver Tumors1." <i>Cancer Res</i> . 53: 2005-2011, (1993).   |
| 72. | Parker, et al. "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains." <i>J. Immunol</i> . 152: 163, (1994).   |
| 73. | Plaksin, D. et al. "A Three-Domain T Cell Receptor Is Biologically Active and Specifically Stains Cell Surface MHC/Peptide Complexes 1,2." <i>J. Immunol</i> . 158: 2218-2227, (1997).  |
| 74. | Polakova, K., et al. "Antibodies Directed Against the MHC-1 Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity1." <i>J. Immunol</i> . 165: 342-348, (2000).  |
| 75. | Porgdor, et al. "Localization, Quantitation, and In Situ Detection of Specific Peptide-MHC Class I Complexes Using a Monoclonal Antibody." <i>Immunity</i> . 6: 715-726, (1997).  |
| 76. | Pujuguet, P. et al. "Expression of Fibronectin ED-A+and ED-B+ Isoforms by Human and Experimental Colorectal Cancer." <i>Am. J. Pathol</i> . 148: 579-592, (1996).   |
| 77. | Puri, et al. "Modulation of the Immune Response in Multiple Sclerosis." <i>J. Immunol</i> . 158: 2471-2476, (1997).   |
| 78. | Salgaller et al. "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Peripheral Blood Lymphocytes Stimulated in Vitro with Synthetic Peptides." <i>Cancer Res</i> . 55: 4972-4979, (1995).   |
| 79. | Scheinberg, et al. "BCR-ABL Breakpoint Derived Oncogene Fusion Peptide Vaccines Generate Specific Immune Responses in Patients with Chronic Myelogenous Leukemia (CML)," [Abstract 1665], American Society of Clinical Oncology 35 <sup>th</sup> Annual Meeting, Atlanta (1999).              |
| 80. | Serwold, et al. "ER aminopeptidases generate a unique pool of peptides for MHC class I molecules." <i>Nature Immunol.</i> 2: 644-651, (2001).   |
| 81. | Slamon, et al., "Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast Cancer that Overexpresses Her2. <i>New.Eng. J. Med</i> . 344: 783-792, (2001). A more detailed description is available in the Online Medelian Inheritance in Man; record *164870          |
| 82. | Stauss et al. "Induction of Cytotoxic T Lymphocytes with Peptides In Vitro: Identification of Candidate T-cell Epitopes in Human Papilloma Virus." <i>Proc. Natl. Acad. Sci. USA</i> . 89: 7871-7875, (1992).   |

EXAMINER


DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
MANNK.032AAPPLICATION NO.  
10/657,022INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Simard, et al.FILING DATE  
September 5, 2003GROUP  
1645

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	83.	Tarli, L. et al. "A High-Affinity Human Antibody That Targets Tumoral Blood Vessels." <i>Blood</i> . 94: 192-198, (1999).
	84.	Toshitani, K., et al. "Expression of a single-chain HLA class I molecule in a human cell line: Presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes." <i>Proc. Natl. Acad. Sci. USA</i> . 93: 236, (1996).
	85.	Tsai, et al. "Identification of Subdominant CTL Epitopes of the GP100 Melanoma-Associated Tumor Antigen by Primary In Vitro Immunization with Peptide-Pulsed Dendritic Cells." <i>J. Immunol.</i> 158: 1796-1802, (1997).
	86.	Tureci, O., et al. "Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens." <i>Proc. Natl. Acad. Sci. USA</i> . 95: 5211-5216, (1998).
	87.	Uger, R. A. and B. H. Barber. "Creating CTL Targets with Epitope-Linked $\beta_2$ -Microglobulin Constructs1." <i>J. Immunol.</i> 160: 1598, (1998).
	88.	Uger, R. A., et al. "Covalent Linkage to $\beta_2$ -Microglobulin Enhances the MHC Stability and Antigenicity of Suboptimal CTL Epitopes1." <i>J. Immunol.</i> 162: 6024, (1999).
	89.	Van de Vijver, et al. "Association with Comedo-type Ductal Carcinoma in Situ and Limited Prognostic Value in Stage II Breast Cancer." <i>New Eng. J. Med.</i> 319: 1239-1245, (1988).
	90.	Van den Eynde, B., et al. "Differential Processing of Class-1-Restricted Epitopes by the Standard Proteasome and the Immunoproteasome." <i>J. Exp. Med.</i> 182: 689-698, (1995).
	91.	Velculiscu V.E. et al. "Analysis of human transcriptomes." <i>Nat. Genet.</i> 23: 387-388, (1999).
	92.	Vose, J.M. "Tumor Antigens Recognized by T Lymphocytes," 10 <sup>th</sup> European Cancer Conference, Day 2, Sept 14, (1999).
	93.	White, J., et al. "Soluble Class I MHC with $\beta_2$ -Microglobulin Covalently Linked Peptides: Specific Binding to a T Cell Hybridoma1." <i>J. Immunol.</i> 162: 2671, (1999).
	94.	Yee, C. et al. "In vivo tracking of tumor-specific T cells." <i>Current Opinion in Immunology</i> . 13: 141-146, (2001),
	95.	Yu, Y.L.Y., et al. "Cutting Edge: Single-Chain Trimers of MHC Class I Molecules Form Stable Structures That Potently Stimulate Antigen-Specific T Cells and B Cells1." <i>J. Immunol.</i> 168: 3145-3149, (2002).

S:\DOCS\MTM\MTM-5775.DOC  
022604.sma

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	